JP2006514946A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514946A5
JP2006514946A5 JP2004559325A JP2004559325A JP2006514946A5 JP 2006514946 A5 JP2006514946 A5 JP 2006514946A5 JP 2004559325 A JP2004559325 A JP 2004559325A JP 2004559325 A JP2004559325 A JP 2004559325A JP 2006514946 A5 JP2006514946 A5 JP 2006514946A5
Authority
JP
Japan
Prior art keywords
alkyl
use according
hydrogen
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004559325A
Other languages
English (en)
Japanese (ja)
Other versions
JP4750421B2 (ja
JP2006514946A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038708 external-priority patent/WO2004052365A2/en
Publication of JP2006514946A publication Critical patent/JP2006514946A/ja
Publication of JP2006514946A5 publication Critical patent/JP2006514946A5/ja
Application granted granted Critical
Publication of JP4750421B2 publication Critical patent/JP4750421B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004559325A 2002-12-06 2003-12-05 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害 Expired - Fee Related JP4750421B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43165002P 2002-12-06 2002-12-06
US60/431,650 2002-12-06
PCT/US2003/038708 WO2004052365A2 (en) 2002-12-06 2003-12-05 Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011014401A Division JP2011105745A (ja) 2002-12-06 2011-01-26 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害

Publications (3)

Publication Number Publication Date
JP2006514946A JP2006514946A (ja) 2006-05-18
JP2006514946A5 true JP2006514946A5 (enExample) 2007-02-01
JP4750421B2 JP4750421B2 (ja) 2011-08-17

Family

ID=32507772

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004559325A Expired - Fee Related JP4750421B2 (ja) 2002-12-06 2003-12-05 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
JP2011014401A Withdrawn JP2011105745A (ja) 2002-12-06 2011-01-26 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
JP2013257181A Expired - Fee Related JP5925178B2 (ja) 2002-12-06 2013-12-12 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
JP2016007291A Pending JP2016084355A (ja) 2002-12-06 2016-01-18 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011014401A Withdrawn JP2011105745A (ja) 2002-12-06 2011-01-26 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
JP2013257181A Expired - Fee Related JP5925178B2 (ja) 2002-12-06 2013-12-12 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
JP2016007291A Pending JP2016084355A (ja) 2002-12-06 2016-01-18 α７受容体結合コリン作動性アゴニストを用いる炎症の阻害

Country Status (14)

Country Link
US (1) US7273872B2 (enExample)
EP (3) EP1949901B1 (enExample)
JP (4) JP4750421B2 (enExample)
CN (2) CN1735414A (enExample)
AT (1) ATE378048T1 (enExample)
AU (1) AU2003298939B2 (enExample)
CA (1) CA2507502C (enExample)
DE (1) DE60317564T2 (enExample)
DK (1) DK1949901T3 (enExample)
ES (2) ES2293086T3 (enExample)
IL (2) IL168787A (enExample)
PT (1) PT1949901E (enExample)
SI (1) SI1949901T1 (enExample)
WO (1) WO2004052365A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ATE378048T1 (de) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
CA2560756A1 (en) 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methods and devices for reducing bleed time using vagus nerve stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
EP2298410B1 (en) * 2004-12-27 2013-10-09 The Feinstein Institute for Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) * 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
JP2009519962A (ja) * 2005-12-19 2009-05-21 コメンティス，インコーポレーテッド 眼投与用局所メカミルアミン製剤およびその使用
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009066107A1 (en) * 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US8722630B2 (en) * 2008-06-13 2014-05-13 The General Hospital Corporation Use of apolipoproteins to decrease inflammation
WO2010037198A1 (en) * 2008-10-03 2010-04-08 Universidade De São Paulo - Usp Pharmaceutical composition, drug screening method and method for treating malaria
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP2515996B1 (en) 2009-12-23 2019-09-18 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
CN102443063B (zh) * 2010-09-30 2013-10-23 成都康弘生物科技有限公司 抗TNFα的人源化Fab和人源化抗体及其用途
EP2640378A4 (en) * 2010-11-18 2014-05-21 Envivo Pharmaceuticals Inc INFLAMMATION TREATMENT WITH CERTAIN NICOTINIC ACID ALPHA-7 RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS
LT2685986T (lt) * 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
RU2611627C2 (ru) * 2011-04-29 2017-02-28 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Алкалоидный эфир и карбаматные производные и их медицинские композиции
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2017178897A2 (en) 2016-04-12 2017-10-19 Arturo Solis Herrera Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
AU2017290353B2 (en) 2016-06-29 2023-05-18 Tulavi Therapeutics, Inc. Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
US11096932B2 (en) 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
WO2018064633A1 (en) * 2016-09-30 2018-04-05 University Of Southern California Nicotinic acetylcholine receptor agonist attenuates ilc2-dependent airway hyperreactivity
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN109652524A (zh) * 2018-11-09 2019-04-19 山西中医药大学 类风湿关节炎大鼠模型中chrna7基因生物信息分析的试验方法
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
WO2020210786A1 (en) 2019-04-12 2020-10-15 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
CN112023050A (zh) * 2020-09-10 2020-12-04 中国科学院深圳先进技术研究院 一种调节巨噬细胞极化状态的方法
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
CN114028570A (zh) * 2021-12-27 2022-02-11 中国药科大学 α7烟碱型胆碱受体激动剂在制备肽酰基精氨酸脱亚氨酶4抑制剂中的用途
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders
US12649059B2 (en) 2022-08-05 2026-06-09 The Feinstein Institutes For Medical Research Methods for reducing bleeding in hemophilia by vagus nerve stimulation to prime platelets
CN119792529B (zh) * 2025-01-16 2026-05-15 山东第一医科大学(山东省医学科学院) 抑制Chrm3受体表达的试剂在制备治疗由脂多糖引起的相关疾病的药物中的应用
CN121041449A (zh) * 2025-07-31 2025-12-02 中国人民解放军军事科学院军事医学研究院 乙酰胆碱受体激动剂在治疗脑膜炎中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659078B1 (en) * 1992-08-31 2003-01-15 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
JP3708962B2 (ja) 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
FR2756826B1 (fr) * 1996-12-05 1999-01-08 Adir Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6323000B2 (en) * 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
JP2002502383A (ja) † 1997-05-30 2002-01-22 ニューロサーアチ・アクティーゼルスカブ ニコチンＡＣｈレセプターに於けるコリン作動性リガンドとしての９−アザビシクロ（３．３．１）ノン−２−エン及びノナン誘導体
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
JP2003512290A (ja) * 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての８ａ−アザライド
AU765142B2 (en) * 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
FR2786770B1 (fr) 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
NZ513575A (en) * 1999-05-04 2003-07-25 Neurosearch As Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators
US6436909B1 (en) 1999-09-17 2002-08-20 Isis Pharmaceuticals, Inc. Antisense inhibition of transforming growth factor-β expression
US20040038875A1 (en) * 2000-03-29 2004-02-26 Greenfield Susan Adele Alpha 7nicotinic receptor screening assays
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
ATE287888T1 (de) * 2000-07-04 2005-02-15 Neurosearch As Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US6492385B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001282874A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6492386B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
EP1358177B1 (en) * 2000-10-13 2006-08-02 NeuroSearch A/S Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
US6884807B2 (en) * 2000-12-01 2005-04-26 Neurosearch, A/S 3-substituted quinuclidines and their use as nicotinic agonists
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
WO2002057275A1 (en) 2001-01-17 2002-07-25 University Of Kentucky Research Foundation Boron-containing nicotine analogs for use in the treatment of cns pathologies
US6479172B2 (en) * 2001-01-26 2002-11-12 Xerox Corporation Electroluminescent (EL) devices
CA2440480A1 (en) * 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
BR0209689A (pt) * 2001-05-15 2006-02-07 Long Island Jewish Res Inst Uso de fragmento de hmg como agente anti-inflamatório
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
BR0212101A (pt) * 2001-08-24 2004-08-24 Pharmacia & Up John Company 7-aza [2.2.1] biciclo-heptanos substituìdos com heteroarila para o tratamento de doenças
CA2460075A1 (en) 2001-09-12 2003-03-20 Donn Gregory Wishka Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
CZ2004408A3 (cs) * 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyklicky substituované kondenzované heteroarylsloučeniny
JP2005510482A (ja) 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
US6849620B2 (en) * 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
JP2005510523A (ja) 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
JP3699392B2 (ja) * 2001-12-04 2005-09-28 本田技研工業株式会社 艇体の接着剤硬化促進装置
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
ATE378048T1 (de) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten

Similar Documents

Publication Publication Date Title
CA2507502A1 (en) Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
US11248010B2 (en) Compounds, compositions, and methods for modulating CFTR
KR102581546B1 (ko) 벤즈아제핀 다이카복스아미드 화합물
ZA200508158B (en) Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
ES2213703T3 (es) Carbamatos derivados de arilalquilaminas.
ES2297533T3 (es) Derivados de 1-piperazina- y 1-homopiperazina-carboxilatos, su preparacion y su aplicacion como inhibidores de la enzima faah.
AR040803A1 (es) Ligandos de receptores canabinoides, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o combinados, para la preparacion de medicamentos
US20090124636A1 (en) Chemical compounds
JP2004510695A5 (enExample)
WO2006034317A3 (en) Chemical compounds
JP2013525458A5 (enExample)
JP2011148809A (ja) 抗腫瘍作用を有するインドリル−３−グリオキシル酸誘導体
PT1354884E (pt) Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf
JP2007500719A5 (enExample)
JP2007530586A5 (enExample)
JP2012510502A5 (enExample)
WO2008096870A1 (ja) アザ架橋環化合物
WO2008117229A4 (en) Muscarinic receptor antagonists
CA2568608A1 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
JP2008502670A5 (enExample)
JP2016028076A5 (enExample)
WO2009035542A3 (en) Guanidine-containing compounds useful as muscarinic receptor antagonists
AR041991A1 (es) Compuestos depirazol para el tratamiento de la hipertension ocular
JP2011519845A5 (enExample)
KR20150070290A (ko) Trp 채널 길항제로서의 6-아미노인돌 유도체